Bristol-Myers to get negative CHMP opinion on renal cancer drugs
NEW YORK: Bristol-Myers Squibb Co said it was told by European regulators that they will recommend against approving the company’s drugs Opdivo and Yervoy to treat first-line renal cancer.
The company said it was notified on Wednesday that would be receiving a negative opinion from the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency.
“We strongly disagree with this opinion. And in the interest of patients, we will pursue a reexamination,” Bristol-Myers CEO Giovanni Caforio said on a conference call to discuss the company’s second quarter earnings.
(Reporting by Michael Erman; Editing by Chizu Nomiyama)
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd